Akers Biosciences, Inc. (AKER) relating to its proposed acquisition by MyMD Pharmaceuticals. Under the terms of the agreement, Akers shareholders are expected to own only 20% of the combined company.
Akers Biosciences, Inc. (AKER) relating to its proposed acquisition by MyMD Pharmaceuticals. Under the terms of the agreement, Akers shareholders are expected to own only 20% of the combined company.